AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05408052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural Puncture Epidural (DPE)
Description: Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance.
Study NCT05408052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standart Epidural
Description: The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance.
Study NCT06102928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined therapy of anlotinib and aumolertinib
Description: Participants were treated with anlotinib and aumolertinib.Aumolertinib mesylate tablets are administered 110 mg orally once a day,and anlotinib hydrochloride capsules were given 12 mg once a day, taken for 2 weeks and then discontinued for 1 week, with a treatment cycle every 21 days. If grade 3 or above treatment-related toxicity occurs, anlotinib can be reduced to 10 mg or 8 mg once daily.
Study NCT05008549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Juice Product
Description: The cranberry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate)~The cranberry juice + lemon balm extract product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + lemon balm extract (300 mg, Robertet Groupe)~The cranberry juice + tart cherry juice product contains 100 % cranberry juice (ingredients: water, cranberry juice concentrate) + 3 g tart cherry powder (Cherry PURE)~The cranberry juice + L-theanine product contains 100% cranberry juice (ingredients: water, cranberry juice concentrate) + 200 mg L-theanine (Suntheanine, Taiyo International)~L-theanine + placebo product contains L-theanine (200 mg, Suntheanine, Taiyo International) + placebo (see 5.2.1)~The placebo product contains water, dextrose, citric acid, malic acid, fumaric acid, natural flavor, Red #40, xanthan gum, Blue #1, gum Arabic, Reb M, Steviol glycosides, and ester gum.
Study NCT05307523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enriched Play Environment with Partial Body Weight Support Harness
Description: A low-tech portable canopy with a partial-body weight harness system that allows a child and their caregiver to play freely in an 81 square foot space, which provides partial body weight offset to support movement and exploration.
Study NCT05307523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Play Environment without Partial Body Weight Support Harness
Description: Child and caregiver will play freely in the 81 square foot play space without being connected to the partial body weight support harness.
Study NCT05298163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol capsules
Description: Calcitriol under the name of Oscal, 0.25 mcg/day (minimum dose) will be given for 6 months, starting at the day of the time when inclusion criteria have been met.
Study NCT05298163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One placebo capsule matching the active drug will be given per day for 6 months, starting at the day of the time when inclusion criteria have been met
Study NCT06156462 — intervention group
Intervention type: DEVICE
Intervention: ResAppDx v.20
Description: Software device measuring cough sounds to aid diagnosis of respiratory diseases
Study NCT05044351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam LX
Description: See arm description
Study NCT05044351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery without NIRAF assistance
Description: Patients undergoing conventional hemithyroidectomy without NIRAF-assistance
Study NCT04914195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
Study NCT04914195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.
Study NCT06239701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LPA+Fitbit Intervention
Description: 1. In-Person LPA+Fitbit Orientation. During an initial, orientation (45 minutes), a study interventionist will provide information regarding the acute and long-term psychological and physical benefits of increasing PA, including prenatally.~2. Telephone PA counseling sessions. A study interventionist will call participants at weeks 2, 4, 6, 8, and 10 of the intervention for a 20-min telephone session.~3. Fitbit activity tracker. With participant permission, a Fitbit account (on Fitbit.com) and study-generated password will be created. In doing so, investigators will have access to the participant activity data throughout the intervention. The Fitbit web-based and mobile apps facilitate goal-setting by allowing participants to easily set goals and change these goals at any point. We will customize each participant account to display daily steps and very active minutes, though they will be encouraged to adjust the display according to their preferences.
Study NCT06239701 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: 1. In-person Fitbit Orientation. Participants will be given information on the public health guidelines for PA during pregnancy, and as well as how to determine if their PA is moderate-intensity. In addition, interventionists will orient participants to the proper use of the Fitbit tracker and offer tips for self-monitoring step counts with the tracker and on the app.~2. Fitbit Activity Tracker. Participants will be given the same Fitbit as in the LPA condition. Participants will not be given any specific step count goals to achieve during the 12-week intervention.~3. Brief Telephone Check-ins. As with the LPA+Fitbit participants, those in the Fitbit Only condition will receive phone calls on weeks 2, 4, 6, 8, 10. These calls will last 5 minutes and be focused entirely on answering any problems related to the Fitbit such as syncing issues, charging the battery, and any other technical problems that may arise. No physical activity counseling will be delivered on these calls.
Study NCT06380556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: The protruding surface of the ShotBlocker was placed on the heel lance procedure site. While applying pressure on the skin through the ShotBlocker, the nurse performed heel lancing with the needle through the opening in the center of the ShotBlocker. During the 10-second waiting phase, the ShotBlocker was kept at the procedure site with the same pressure. Then ShotBlocker was removed from the skin and routine capillary blood collection procedure was performed.
Study NCT06380556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Description: The vibration device was placed on the infant's left extremity in the mid/lateral region just below the knee where the sural nerve passes. The device was secured to the extremity with a gauze bandage. The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse punctured the heel with a needle. Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from the baby's extremity and routine capillary blood collection procedure was performed.
Study NCT04641585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Patients affected by Brugada Syndrome 1
Description: ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
Study NCT04641585 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients affected by Brugada Syndrome 1
Description: ECG analysis by Machine Learning algorithms and blood collection for the transcriptomic study of markers possibly associated with the disease
Study NCT06501833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11+ KIDS PROGRAM
Description: The experimental group will perform eight weeks of FIFA 11+ kids program (3/week).
Study NCT06501833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REGULAR TRAINING
Description: The control group will be continuing their regular training
Study NCT06342466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3mg/m2 sc weekly
Study NCT06342466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4mg per day taken orally on 1-21 of repeated 28-day cycles
Study NCT06342466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg-40mg weekly
Study NCT04783480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Birthly
Description: Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.
Study NCT04783480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Subjects will participate in childbirth education at their own discretion.
Study NCT05965505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT-1003
Description: AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Study NCT05738668 — intervention group
Intervention type: OTHER
Intervention: Description of clinical characteristic
Description: This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study.
Study NCT05157984 — intervention group
Intervention type: PROCEDURE
Intervention: ZPOEM
Description: Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
Study NCT06233981 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy
Description: All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
Study NCT06233981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: One week before or during the radiotherapy, patients receive concurrent Tislelizumab at a dose of 200mg. Subsequently, Tislelizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Tislelizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
Study NCT05842434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Felix
Description: Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
Study NCT04177004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT
Study NCT04177004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT04177004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FTBI
Study NCT04177004 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fractionated Stereotactic Radiation Therapy
Description: Undergo FTBI
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goat Milk
Description: Given human lysozyme goat milk PO
Study NCT04177004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV
Study NCT04177004 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin
Description: Given IV
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Given PO
Study NCT04335461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cephalomedullary nailing of extracapsular hip fracture
Description: All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
Study NCT04335461 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cephalomedullary nailing of extracapsular hip fracture
Description: All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
Study NCT04335461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cephalomedullary nail
Description: Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
Study NCT04335461 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cephalomedullary nail
Description: Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
Study NCT04335461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regional Anesthetics
Description: Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
Study NCT06406426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
Description: Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
Study NCT06144567 — intervention group
Intervention type: DRUG
Intervention: Upadacitinib
Description: As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
Study NCT05129683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebellar stimulation group
Description: Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given
Study NCT05129683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebral (M1) stimulation group
Description: single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
Study NCT05129683 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
Study NCT05476757 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169
Description: rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
Study NCT04464473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
Study NCT04464473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
Study NCT05546112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B
Description: A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve
Study NCT05546112 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation using YPS-401B
Description: A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
Study NCT06634342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HCV RNA Rapid testing
Description: Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
Study NCT06030986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ILCOR Utstein OHCA Core Outcome
Description: ILCOR Utstein OHCA Core Outcome
Study NCT05572671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laboratory task modeling smoking lapse behavior
Description: Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
Study NCT03729817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Submaximal balloon angioplasty
Description: An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
Study NCT05777577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic therapy
Description: probiotic including bifidobacterium
Study NCT05149859 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: (no intervention)
Study NCT04943276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embr Device
Description: The Embr thermal device will be worn at all times from study start to the study endpoint.
Study NCT04325204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-based Home Activity Toolbox (Faith-HAT)
Description: They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project.
Study NCT05703269 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: single fraction stereotactic radiosurgery (SSRS)
Description: SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.
Study NCT05703269 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fractionated stereotactic radiosurgery (FSRS)
Description: FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
Study NCT05076695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)